Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
2024年 3月 27日
Read MoreZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
2024年 3月 13日
Read MoreZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
2024年 3月 06日
Read MoreZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
2024年 2月 27日
Read MoreZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
2024年 1月 25日
Read MoreZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
2024年 1月 11日
Read More